An interventional study of Non-thermal photodynamic therapy in Venous Leg Ulcer (VLU), Venous Leg Ulcers (VLUs) and Wound Closure, sponsored by Dr. Ahmed Kayssi. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Dr. Ahmed Kayssi · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Varicose Ulcer with a site in Canada — 2 open to participants now, 2 under way, 1 of them phase 3. Varicose Ulcer · Canada.
Among the 22 studies in Varicose Ulcer with a site in Canada, this one is the 14th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 22nd registered.
371 studies on the registry are indexed under Varicose Ulcer; 74 are open to participants now.
Browse Varicose Ulcer studies →2 of the 22 studies in Varicose Ulcer with a site in Canada are open now. Recruiting first, the newest first:
MediWound Ltd · Sites in Canada, United States, Austria and 6 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4
First in 1999; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 20 is below the median of 60 across 309 interventional studies indexed under Varicose Ulcer.
Median enrollment 101 across the 18 interventional studies, 141 across the 4 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 22 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr. Ahmed Kayssi as lead sponsor.
Dr. Ahmed Kayssi has 1 study filed under Varicose Ulcer — fewer than ten, so there is no comparison to draw.
2 of the studies in Varicose Ulcer with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568627Phase 3MediWound LtdA Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) | 2026-12 |
| NCT07947589Dr. Ahmed KayssiToeFX Light Therapy for Chronic Venous Leg Ulcers | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Varicose Ulcer with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.
A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.
The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.
This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.
The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.
Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.
A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.
ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.
This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure
Device: Non-thermal photodynamic therapy
Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation
Also known as: ToeFX, ClearToe Serum
Treatment adherence
Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions
Time frame: Baseline through Visit 12/ end of treatment (up to 12 weeks)
Safety: Adverse Events
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs
Time frame: Baseline through Healing Confirmation Visit (up to 14 weeks)
Percent Change in Wound Area From Baseline
Percent change in wound area (cm²) from baseline
Time frame: Baseline, week 4, week 8, and week 12
Complete wound epithelialization
Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician
Time frame: 12 weeks
Time to complete wound healing
Time (days) from baseline to complete epithelialization
Time frame: 12 weeks
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
Change in wound bed characteristics measured using the BWAT
Time frame: Baseline to 12 weeks/ end of treatment
Change in pain score
Change in pain score (0-10 Numeric Rating Scale)
Time frame: Baseline to 12 weeks/ end of treatment
Change in health-related quality of life
Change in EQ-5D-5L score
Time frame: 12 weeks/ end of treatment
Patient satisfaction
Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire
Time frame: 12 weeks/ end of treatment
Clinician feasibility
Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow
Time frame: 14 weeks or earlier if wound healing
Absolute Change in Wound Area From Baseline
Absolute change in wound area (cm²) from baseline
Time frame: Baseline, week 4, week 8, and week 12
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.
Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.
Of 67 non-industry interventional studies with no phase under Varicose Ulcer, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 65. This study's planned 11 months is below that.
Counting every sponsor, half of 134 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.